ArticleAnnals of clinical and translational neurology2025
Relevance of Kappa and Lambda Free Light Chains in Autoimmune Astrocytopathy Associated With Anti-GFAP Antibodies.
Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05428605 (In Vitro Study of the Efficacy of Different Immunomodulators on the Th17/Treg Balance in a Cohort of Relapsed Membranous Nephropathy), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
In Vitro Study of the Efficacy of Different Immunomodulators on the Th17/Treg Balance in a Cohort of Relapsed Membranous Nephropathy
Who cites it
3 citing papers in PubMed.
- Early Clinical and Cerebrospinal Fluid Predictors of 1-Year Recurrence in Autoimmune GFAP Astrocytopathy.Annals of clinical and translational neurology · 2026Article
- Intrathecal immunoglobulin production in the diagnosis, prognosis, and monitoring of autoimmune diseases of the central nervous system.Journal of translational autoimmunity · 2026Review
- Current and Future Biomarkers in the Diagnosis of Autoimmune Encephalitis: A Review of Biomarker Detection Techniques and Their Performance.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe kappa-free light chain (κ-FLC) index is known to be highly sensitive and specific for diagnosing multiple sclerosis (MS), while little is understood about lambda (λ)-FLC. This study assessed the κ-FLC and λ-FLC indices in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy.
methodsThis multicenter study compares κ-FLC and λ-FLC indexes among patients with autoimmune GFAP astrocytopathy and sex- and age-matched MS (positive control group) as well as symptomatic controls (headaches and small cerebral vessel disease, as the negative control group). We describe the correlation of both indexes with clinical variables and outcomes in the GFAP astrocytopathy cohort.
resultsA total of 93 patients were included (31 in each group). The median κ-FLC index was higher in the MS group (65.5 [35.7; 118.3]) compared to the GFAP astrocytopathy group (26.1 [11.4; 78.4], p = 0.062). With a κ-FLC index threshold of 6.1, the proportion of patients with a positive κ-FLC index was similar between the MS (94%) and GFAP-astrocytopathy groups (84%, p = 0.425). The median λ-FLC index was higher in the GFAP astrocytopathy group (45.5 [28.4; 96.9]) than in the MS group (10.6 [2.2; 29.1], p < 0.001). In the GFAP-astrocytopathy group, both CSF λ-FLC and the λ-FLC index at baseline were correlated with the last follow-up mRS (⍴ = 0.46, r
conclusionThe κ-FLC index alone cannot distinguish between autoimmune GFAP astrocytopathy and MS. We indicate a potential diagnostic and prognostic role of the λ-FLC index in GFAP astrocytopathy that needs confirmation in independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.